Reach Us +441474556909


Pharmacological Study and Overcome the Cardiotoxicity Associated with Anticancer Drug Doxorubicin

Doxorubicin, also known as Adriamycin, is an anthracycline drug commonly used in cancer chemotherapy. Adriamycin is being used clinically for solid tumours, e.g. adenocarcinoma of breast, malignant sarcomas, neuroblastoma, ovarian cancer, small lung cancer as well as hematologic malignancies including lymphomas and leukaemias. In this review we can answers different questions from which mainly we focus on that how we can prevent its toxicity and interactions with other agents and which parameters we use for to overcome this. Unfortunately, its therapeutic potential can be limited to cardiotoxicity so for to overcome this liposomal encapsulation of doxorubicin done for to overcome toxicity problems. However its use has been limited by its major clinical side effect, cardiotoxicity. Toxic effect of Adriamycin can be prevented by using different pharmacologic substances like antioxidants. Adriamycin produces its antineoplastic effect by multiple mechanisms and the exact mechanism of action of Adriamycin is still unknown. The proposed mechanism of the antineoplastic effect of Adriamycin at the cellular level is drug binding to DNA by intercalation between base pairs and inhibition of RNA synthesis by template disordering and steric obstruction.


Muhammad Zeeshan Zafar, Huma Sabir

Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+
Flyer image

Abstracted/Indexed in

  • Index Copernicus
  • Genamics JournalSeek
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • CINAHL Complete
  • Social care institute for Excellence(SCIE)
  • Scimago
  • Ulrich's Periodicals Directory
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • WorldCat
  • Proquest Summons
  • MIAR
  • ResearchGate
  • University Grants Commission
  • Secret Search Engine Labs